WO1997028832A1 - Composition for sealing wounds - Google Patents
Composition for sealing wounds Download PDFInfo
- Publication number
- WO1997028832A1 WO1997028832A1 PCT/US1997/001901 US9701901W WO9728832A1 WO 1997028832 A1 WO1997028832 A1 WO 1997028832A1 US 9701901 W US9701901 W US 9701901W WO 9728832 A1 WO9728832 A1 WO 9728832A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adhesive
- matrix
- composition
- coagulation
- fibrinogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- This invention relates to a composition of and method for producing a hemostatic dressing consisting of a carrier, a binding agent and substances of animal or human origin that are conducive to the coagulation of blood and/or the healing of wounds, and is capable of stopping bleeding, especially arterial bleeding.
- a composition of and method for producing a hemostatic dressing consisting of a carrier, a binding agent and substances of animal or human origin that are conducive to the coagulation of blood and/or the healing of wounds, and is capable of stopping bleeding, especially arterial bleeding.
- Background of the Invention It has been known to use various types of materials containing blood clotting substances to close and cover wounds. A difficulty in producing these materials is the necessity of preventing the coagulation substances, notably fibrinogen and thrombin, from reacting prior to use.
- One approach to preventing the clotting factors from reacting with each other prior to use has been to provide a layered collagen sheet containing fibrinogen on one layer and thrombin on an adjacent layer as described in U.S.
- Patents 4,606,337 and 4,683,142 A disadvantage of this method is that the fibrinogen and thrombin are not in close contact with each other and must mix after being applied to the wound. This could cause a delay in the onset of coagulation. Another disadvantage of this method is the necessity of having to manufacture several different layers and then assemble them in the proper order. Furthermore, this patent describes the use of only glycoproteins as the carrier matrix and is not applicable to other materials.
- a tissue adhesive is disclosed in U.S. Patent 4,600,574 which uses a tissue compatible material selected from the group consisting of collagen, gelatin and polysaccharide.
- This material is impregnated with fibrinogen and Factor XIII and then lyophilized This material does not contain thrombin, and relies on endogenous thrombin production at the wound site. This is an obvious disadvantage especially where there is consumptive coagulopathy or any other reason for insufficient thrombin to be produced to rapidly form a clot with the fibrinogen supplied on the material being applied to the wound.
- U.S. Patent 4,442,655 discloses the preparation, manufacture and use of a preparation in which the fibrinogen and thrombin are allowed to react to form the material which is then used as a wound toilet material, a filling material for bone cavities and/or as a support material for other substances. This is not a hemostatic product.
- a composition for sealing and healing wounds is disclosed in U.S. Patent 4,453,939.
- This composition is a collagen matrix to which fibrinogen and thrombin are added in the presence of an organic solvent such as alcohols, ketones, ethers, esters, and halogenated hydrocarbons.
- organic solvents are known to inactivate and denature proteins such as fibrinogen and thrombin with denaturation occurring more rapidly as the temperature is increased.
- the manufacturing process must occur at cold temperatures. At cold temperatures there is still the possibility that the clotting proteins will be denatured by these organic solvents causing the partial or complete inactivation of the clotting proteins.
- a further disadvantage is that it is an economic and logistic disadvantage to have a manufacturing process which requires refrigerator temperatures.
- the coagulation constitutents are dispersed throughout the collagen matrix, and may not be available at the surface of the matrix in sufficient quantities to promote coagulation.
- the object of this invention is to provide a hemostatic dressing which is capable of stopping severe bleeding such as that which occurs when major blood vessels are severed.
- the present invention provides a composition for a hemostatic bandage comprising a carrier, sufficient coagulation constituents to allow blood clot formation, wherein the constituents are in an environment such that they react only when used.
- the bandage includes a substance which allows the coagulation constituents to adhere to the carrier, hence when the bandage is placed on a bleeding wound and comes in contact with body fluids, the coagulation constituents react to form a clot which stops the bleeding. It is not necessary for the body fluids to contain fibrinogen, thrombin or other coagulation constituents to achieve hemostatic activity.
- the adhesive material that adheres the coagulation constitutents to the carrier is a viscous liquid that does not easily penetrate very deeply into the carrier, and therefore provides a higher concentration of coagulation factors on the surface of the carrier where they are needed.
- the viscous nature of the material also provides improved adhesiveness to the carrier.
- the present invention provides a composition for sealing and healing wounds and which may be stored for a lengthy period while maintaining efficacy.
- the composition comprises a carrier which may be absorbable (so as to be able to be used internally) such as alginic acid or one of its salts, or any one of a number of other polysaccharides such as cellulose, gum xanthan, carrageenan or pectin. Gelatin, collagen or other protein capable of being formed into a carrier may also be used.
- the carrier may be non-absorbable to be used externally. Examples of non-absorbable carriers are surgical gauze, clinical felt, polyurethane foam and other material commonly used in medical practice.
- Said carrier is coated on one side with a viscous liquid such as propylene glycol, glycerol or a low molecular weight polyethylene glycol that is sufficiently tacky to allow the coagulation constituents to adhere to the carrier.
- a viscous liquid such as propylene glycol, glycerol or a low molecular weight polyethylene glycol that is sufficiently tacky to allow the coagulation constituents to adhere to the carrier.
- the carrier may also be coated with water in a low concentration and/or at a low pH so as not to support reaction of the coagulation factors.
- the coagulation constituents may be applied in a dried or powdered form and include 1) a thrombin component containing thrombin substances which form thrombin in the presence of body fluids, or a mixture of such substances, 2) a fibrinogen component containing fibrinogen, fibrinogen-containing Factor XIII, or a mixture of such substances.
- the mixture of 1 and 2 may contain additives such as calcium ions, antibiotics or other anti-infection medicaments, vasoconstrictive substances such as adrenaline, and/or growth factors. -4 -
- the carrier may be in the form of a foam, web, film or when possible, as in the case of cellulose and cotton gauze, it may be woven. Such materials are prepared in a manner well known to those skilled in the art. Additionally, an adhesive backing may be applied to the carrier.
- the fibrinogen may be of human or animal origin and may be applied in the range of 0.1 to 20 mg/cm 2 , preferably from 1 to 10 mg/cm 2 of surface area of the substrate.
- the fibrinogen may or may not contain Factor XIII.
- fibrinogen containing 0.5 to 20 units of Factor XIII per mg of fibrinogen is employed, preferably between 2 and 10 units per mg of fibrinogen.
- Factor XIII may be added separately to increase its concentration if desired.
- the fibrinogen may be in any dry form, preferably in a powdered form to allow rapid dissolution when in contact with body fluids.
- the thrombin may be of human or animal origin and may be applied in the range of 1 to 20 NIH units/mg fibrinogen, preferably 3 to 12 NIH units/mg fibrinogen.
- any substance or substances that liberate thrombin may replace thrombin. Examples of such factors include Factor X or Xa plus prothrombin, any of the various enzymes from snake venom that liberate thrombin from prothrombin such as that from the viper Echis carinatus plus prothrombin, or enzymes which convert fibrinogen to fibrin such as that from the viper Bothrops atrox plus prothrombin.
- coagulation factors In addition to the coagulation factors, other substances such as growth factors to promote healing, calcium ions to aid coagulation and Factor XIII activity, adrenaline or other substances to constrict blood vessels to aid in hemostasis and bactericides to prevent infection.
- the carrier is coated on one or both sides with a sticky biocompatible non-aqueous substance, that does not denature the coagulation factors nor participate in or activate the enzymatic clotting reaction involving the coagulation factors.
- a sticky biocompatible non-aqueous substance that does not denature the coagulation factors nor participate in or activate the enzymatic clotting reaction involving the coagulation factors.
- Such substances include but are not limited to carbohydrates, such as saccharides, for example monosaccharides (such as glucose), oligosaccharides (such as maltose), polysaccharides (such as glycogen).
- the sticky, biocompatible substances could also be a polyhydric alcohol such as glycerol or other organic adhesive polymers, such as polyethylene glycol having a molecular weight of about 200 to 400 daltons, and propylene glycol.
- the carrier may be lyophilized in the presence of the viscous liquid.
- the carrier may be coated with a very small amount of water preferably at
- the dry powdered coagulation factors and other substances may be mixed together and added at once or they may be added sequentially.
- the solids are preferably milled to a fine powder to enhance their solubility and when added together it is preferable to mix them thoroughly in a blender before binding them to the carrier.
- the composition is a solid, fibrous matrix, such as cotton gauze or alginic acid, suitable for placement as a pad applied over or inserted into an open bleeding wound.
- a mixture of intermingled particles of powdered coagulation factors, preferably fibrinogen and thrombin, are present alongside one another in the matrix to readily interact when moistened by blood or other aqueous body fluids that provide an aqueous liquid reaction medium.
- the particles are adhered to the sold matrix by a viscous nonaqueous adhesive material, such as a viscous polysaccharide, polyethylene glycol, or petroleum jelly, that interferes with or does not participate in the enzymatic clotting reaction involving the coagulation factors at room temperature and at physiologic pH (about 7.3-7.4).
- a viscous nonaqueous adhesive material such as a viscous polysaccharide, polyethylene glycol, or petroleum jelly, that interferes with or does not participate in the enzymatic clotting reaction involving the coagulation factors at room temperature and at physiologic pH (about 7.3-7.4).
- the thrombin/fibrinogen reaction is hydrolytic and requires an aqueous medium for the fibrin clot to be formed.
- the viscous adhesive is substantially free of water, and therefore substantially prevents fibrin clot formation.
- the nonaqueous viscous adhesive preferably contains less than 15% by weight water, preferably less than 10%, most preferably less than 3% water. Weights are expressed in weight percent of the final product (which includes matrix, viscous adhesive, and coagulation factors).
- the polysaccharide or other adhesive material is sufficiently tacky to adhere to the matrix a sufficient amount of the commingled particles of the powdered coagulation factors to form a clot when the matrix is exposed to an aqueous solution, blood from a wound, or body fluids, such as serosanguinous fluid or cerebrospinal fluid.
- the clot that is formed is sufficient to reduce or stop bleeding or leaking from a wound, such as an abrasion, spinal needle puncture, laceration, avulsion or surgical incision.
- the invention also includes clotting compositions made by the method of adhering particles of the powdered coagulation factors to the matrix, such as a cotton gauze or an alginic acid matrix.
- the particles are adhered to the matrix by the viscous adhesive material, which maintains the physically commingled particles within the matrix, near the surface, but inhibits clotting action until the matrix is exposed to an aqueous medium that dissolves the particles and permits participation of the coagulation factors in the clotting cascade, and formation of a fibrin clot.
- the method by which the composition is made includes applying the viscous adhesive to the matrix, followed by application of a mixture of solid thrombin and fibrinogen particles to the matrix.
- the thrombin and fibrinogen particles can be suspended in the nonaqueous viscous adhesive liquid that inhibits or prevents the hydrolytic reaction and fibrin clot formation.
- This viscous mixture containing the particles can be applied as a slurry directly to the surface or surfaces of the matrix.
- the high viscosity of the adhesive inhibits abso ⁇ tion of the adhesive and suspended particles deep into the matrix, such that the particles remain relatively available for participation in clotting reactions during use.
- the composition can be prepared at and stored without refrigeration. Preparation and storage can occur, for example, at 20-35°.
- Methods of use of the composition include applying the composition to the surface of an abrasion, laceration, puncture, avulsion, surgical incision or other injury to promote clotting and stop bleeding.
- the composition can also be packed into open wounds by physicians or emergency medical personnel, to promote coagulation and diminish blood loss.
- the composition is particularly useful at stopping life-threatening arterial blood loss that can lead to exsanguination. It is preferred to apply one of the coated surfaces of the composition directly to the source of bleeding, such as an abraded dermal surface.
- EXAMPLE 1 A 2% solution of low viscosity sodium alginate from Macrocystis pyrifira (Sigma Chemical Co. , St. Louis, MO) was prepared by dissolving the alginate in water at 60°. Ten mL of this solution was placed in a round aluminum mold 4.4 cm in diameter (15 cm 2 ), frozen at -20° and lyophilized. The lyophilization was carried out with the product at room temperature, the condenser at -40° to -50° and the vacuum at 30 to 60 millitorr.
- the resulting pad was dipped at room temperature into a suspension of 100 mg bovine fibrinogen (56% protein, 95% clottable, Sigma Chemical Co. , St. Louis, MO) and 6 mg bovine thrombin [56 NIH units/mg (as determined by direct comparison to NIH thrombin reference standard J), Sigma Chemical Co., St. Louis, MO] in 3 mL polyethylene glycol (average molecular weight 300, viscosity 5.8 centistokes or 6.5 centipoise at 210°F, Sigma Chemical Co., St. Louis, MO) so as to coat the pad at room temperature (about 25 °C) with the fibrinogen thrombin mixture.
- bovine fibrinogen 56% protein, 95% clottable, Sigma Chemical Co. , St. Louis, MO
- bovine thrombin [56 NIH units/mg (as determined by direct comparison to NIH thrombin reference standard J), Sigma Chemical Co., St. Louis, MO] in 3 m
- the pad was kept at room temperature for 15 to 30 minutes to ensure that no clot would form. Then, in order to test the ability of the resulting pad to form a clot when exposed to an aqueous environment the pad was placed in a small dish (4.4 cm diameter) containing 4 mL of 40 mM Tris, pH 7.4 and 5 mM CaCl 2 at 37°. In less than 30 seconds, a clot formed which adhered tightly to the bottom of the dish.
- test described in this and other examples can be used as an assay to select other adhesive materials, reactant amounts, reaction conditions, and other process parameters that will produce a product that forms a clot when exposed to body fluids under conditions of use.
- a pad of sodium alginate prepared as in Example 1 was dipped in a 4.4 cm diameter aluminum dish containing 100 mg of bovine fibrinogen, 5 mg of bovine thrombin (the same proteins that were described in Example 1) in 3 mL of glycerol (viscosity of 1497 cps at 20°C, Sigma Chemical Co., St. Louis, MO). After standing for 15 to 30 minutes the pad was dipped in an aluminum dish (4.4 cm diameter) containing 2 mL of 40 mM Tris pH 7.4 and 5 mM CaCl 2 at 37°. In less than 30 seconds, a clot formed which adhered tightly to the bottom of the dish.
- EXAMPLE 3 Nine mL of a sodium alginate solution prepared as in Example 1 was mixed with 1 mL of polyethylene glycol of average molecular weight 300 and placed in a 4.4 cm diameter aluminum dish and lyophilized as in Example 1. Similarly, 8.5 mL of this solution was mixed with 1.5 mL of polyethylene glycol, average molecular weight 400 (viscosity 7.3 centistokes or 8.2 centipoise at 210°F, Sigma Chemical Co., St. Louis, MO) and 8 mL was mixed with 2 mL of polyethylene glycol average molecular weight 400 or 2 mL of polyethylene glycol average molecular weight 400 or 2 mL of polyethylene glycol average molecular weight 300 and lyophilized as above. The pads produced this way were more flexible than those made without polyethylene glycol and the flexibility and tackiness increased with increasing amounts of polyethylene glycol. There were no noticeable difference between the 300 and 400 molecular weight polyethylene glycol. EXAMPLE 4
- a 2% solution of carrageenan (vegetable gelatin from Irish Moss, Type 1, Sigma Chemical Co. , St. Louis, MO) was prepared by dissolving the carrageenan in water at 60° to 80°. Ten mL of this solution was placed in a round aluminum mold 4.4 cm in diameter (15 cm 2 ), frozen at -20° and lyophilized. Eight mL of this solution was mixed with 2 mL of polyethylene glycol average molecular weight 400 and placed in a round aluminum mold 4.4 cm in diameter and lyophilized. The lyophilization was carried out with the product at room temperature, the condenser at -40° to -50° and the vacuum at 30 to 60 millitorr.
- the pad without the polyethylene glycol was brittle while the one with polyethylene glycol was very soft, pliable and tacky.
- the pad that was prepared with polyethylene glycol was placed in a small dish containing 100 mg bovine fibrinogen (56% protein, 95% clottable, Signa Chemical Co. , St. Louis, MO) and 7 mg bovine thrombin [56 NIH units/mg (as determined by direct comparison to NIH thrombin reference standard J) bovine thrombin, Sigma Chemical Co. , St. Louis, MO].
- the pad was pressed firmly into the dry powder so as to impregnate the powder into the pad.
- the pad was kept at room temperature for one hour to ensure that no clot would form.
- the pad was placed in a small dish (4.4 cm diameter) containing 3 mL of 40 mM Tris, pH 7.4 and 5 mM CaCl 2 at 37°. In 30 to 40 seconds, a clot formed which adhered tightly to the bottom of the dish.
- EXAMPLE 7 A gauze bandage was folded into a three layer square of 36 cm 2 . Two mL of polyethylene glycol, molecular weight 400 daltons, was spread evenly over the gauze. A mixture of 100 mg of fibrinogen and 4 mg of thrombin were applied to the gauze. Four mL of Tris buffer, pH 7.4 and 5 mM CaCl 2 was placed in a plastic dish so as to form a shallow layer. The solution was heated to 37° and the thrombin and fibrinogen containing gauze was placed in the dish. In less than one minute, the gauze was firmly attached to the bottom of the dish by the fibrin clot which formed.
- EXAMPLE 8 A carrageenan pad prepared without polyethylene glycol as in Example 5 was coated with a thin film of petroleum jelly. Then 100 mg bovine fibrinogen (56% protein, 95% clottable, Sigma Chemical Co., St. Louis, MO) and 7 mg bovine thrombin [56 NIH units/mg (as determined by direct comparison to NIH thrombin reference standard J), Sigma Chemical Co., St. Louis, MO] was impregnated into the pad. The pad was kept at room temperature for one hour to ensure that no clot would form.
- the pad was placed in a small dish (4.4 cm diameter) containing 3 mL of 40 mM Tris pH 7.4 and 5 mM CaCl 2 at 37°. In 30 to 40 seconds, a clot formed which adhered tightly to the bottom of the dish.
- EXAMPLE 9 A 4% solution of low viscosity sodium alginate from Macrocystis pyrifira (Sigma Chemical Co. , St. Louis, MO) was prepared by dissolving the alginate in water at 60° . Fifteen mL of this solution was placed in a round aluminum mold 4.4 cm in diameter (15cm 2 , frozen at -20°) and lyophilized. The lyophilization was carried out with the product at room temperature, the condenser at -40° to -50° and the vacuum at 30 to 50 millitorr. The resulting cake was 10 mm thick. The cake was attached to a Bertek Inc. (St.
- Albans VT medical laminate consisting of copolyester film 325, PSA adhesive 737 and release liner 2114.
- the adhesive allowed the pad to adhere firmly to the film.
- the resulting pad was dipped at room temperature into a suspension of 200 mg bovine fibrinogen (56% protein, 95% clottable, Sigma Chemical Co, St. Louis, MO) and 10 mg bovine thrombin [56 NIH units/mg (as determined by direct comparison to NIH thrombin reference standard J, Sigma Chemical Co. , St. Louis MO] in 3 mL polyethylene glycol (average molecular weight 300, viscosity 5.8 centistokes at 210° F, Sigma Chemical Co., St.
- the pad was placed in a small dish (44 x 12.5 mm) containing 4 mL of 40 mM Tris, pH 7.4 and 5 mM CaCl 2 at 37°C. Pressure was applied to the pad by taping the ends of the film firmly to the tabletop. After two minutes, the tape was peeled from the tabletop and was easily separated from the pad. The pad strongly adhered to the dish due to the fibrin clot.
- this type of hemostatic dressing can be applied with pressure by adhering the film to the skin adjacent to the wound. As the film is permeable to air but not to liquids, it can be left in place until healing occurs or the film can be replaced when necessary.
- the film could be applied with pressure and secured in place with surgical staples. After the clot has set, the staples would be removed and the film peeled from the pad leaving the clot and the absorbable pad in place.
- the pad could be attached to an absorbable mesh (made of polyglycolic acid for example) instead of the copolyester film.
- the term "viscous" means having a viscosity higher than 100 centipoise at 20°C.
- the viscous liquid has a viscosity of at least 1000 centipoise, for example 1 x 10 3 to 1 x IO 16 centipoise at 20°C.
- the viscosities (in centipoise) of some of the disclosed adhesive materials at 20 °C include: sucrose at 2.8 x 10 6 , glycerol at 1 ,490, and glucose at 9.1 x 10 15 .
- nonaqueous liquid is one that has less than 15% water by weight, although some embodiments of the nonaqueous liquid have less than 3 % water by weight, for example 1-3% water by weight.
- Body fluids that activate clotting include liquid blood (including whole blood or plasma), serosanguinous fluid, cerebrospinal fluid, and other fluids produced by the human body that provide a continuous medium that is sufficiently aqueous, and at a physiological pH, that initiates the clotting cascade.
- a “saccharide” is a sugar, which is a type of carbohydrate. Examples include maltose, glucose, ethyrose, arabinose and fructose.
- a monosaccharide (such as glucose) is a saccharide that is not hydrolyzable into smaller units.
- a disaccharide (such as maltose) yields two equivalents of the monosaccharide upon hydrolysis under mildly acidic conditions.
- An oligosaccharide is a saccharide polymer continuing up to eight saccharide subunits.
- a polysaccharide is a polymer in which the number of subunits is greater than eight, for example 100-300 subunits.
- Propylene glycol refers to 1,2-propaneglycol.
- Glycerol is 1,2,3- propanetriol.
- Petroleum jelly is also known as petrolatum (U.S. P.) or mineral jelly.
- Polyethylene glycol is a condensation polymer of ethylene glycol, having average molecular weights ranging from about 200 to 6000. 28832
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1121696P | 1996-02-06 | 1996-02-06 | |
US60/011,216 | 1996-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997028832A1 true WO1997028832A1 (en) | 1997-08-14 |
Family
ID=21749364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/001901 WO1997028832A1 (en) | 1996-02-06 | 1997-02-06 | Composition for sealing wounds |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2245585A1 (en) |
WO (1) | WO1997028832A1 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999056798A1 (en) * | 1998-05-07 | 1999-11-11 | Genzyme Corporation | Compositions comprising hemostatic compounds and bioabsorbable polymers |
WO1999059647A1 (en) * | 1998-05-19 | 1999-11-25 | The American National Red Cross | Hemostatic sandwich bandage |
WO2000038752A1 (en) * | 1998-12-23 | 2000-07-06 | Aventis Behring Gmbh | Fibrin-based glue granulate and corresponding production method |
EP1172115A1 (en) * | 2000-02-22 | 2002-01-16 | Hogy Medical Co., Ltd. | Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
WO2002058750A2 (en) * | 2001-01-25 | 2002-08-01 | Nycomed Pharma As | A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
US6447774B1 (en) | 1998-11-18 | 2002-09-10 | Aventis Behring Gmbh | Stabilized protein preparations for a tissue adhesive |
US6897348B2 (en) | 2001-12-19 | 2005-05-24 | Kimberly Clark Worldwide, Inc | Bandage, methods of producing and using same |
EP1588722A1 (en) * | 2003-01-20 | 2005-10-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Hemostatic materials |
US6967261B1 (en) | 2001-12-28 | 2005-11-22 | Kimberly-Clark Worldwide | Bandage, methods of producing and using same |
US7052713B2 (en) | 2001-02-13 | 2006-05-30 | Nycomed Pharma As | Carrier with solid fibrinogen and solid thrombin |
US7098315B2 (en) | 2001-01-25 | 2006-08-29 | Nycomed Pharma As | Method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
EP1759718A1 (en) * | 2004-05-21 | 2007-03-07 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Tissue closing preparation |
US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
DE102008034364A1 (en) | 2007-08-03 | 2009-02-05 | Birgit Riesinger | Hemostatic wound care article |
EP2056756A2 (en) * | 2006-08-04 | 2009-05-13 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
US7572769B2 (en) | 1998-12-23 | 2009-08-11 | Csl Behring Gmbh | Fibrin adhesive granulate and method for its preparation |
US8277837B2 (en) | 2006-01-11 | 2012-10-02 | Entegrion, Inc. | Hemostatic textile |
WO2013082073A1 (en) | 2011-12-02 | 2013-06-06 | Ethicon, Inc. | Hemostatic bioabsorbable device with polyethylene glycol binder |
US20140046255A1 (en) * | 2009-09-18 | 2014-02-13 | Bioinspire Technologies, Inc. | Free-standing biodegradable patch |
EP2752203A1 (en) * | 2008-04-25 | 2014-07-09 | Medtrade Products Ltd. | Haemostatic material |
US9131929B2 (en) | 2007-08-06 | 2015-09-15 | Stb, Ltd. | Methods and dressings for sealing internal injuries |
US9271925B2 (en) | 2013-03-11 | 2016-03-01 | Bioinspire Technologies, Inc. | Multi-layer biodegradable device having adjustable drug release profile |
US20160106883A1 (en) * | 2014-10-15 | 2016-04-21 | Stb, Ltd. | Processes For Mixing Fibrinogen and Thrombin Under Conditions That Minimize Fibrin Formation While Preserving Fibrin-forming Ability, Compositions Produced by These Processes, and the Use Thereof |
AU2015202402B2 (en) * | 2008-04-25 | 2016-06-16 | Medtrade Products Limited | Haemostatic material |
JP2016523679A (en) * | 2013-07-09 | 2016-08-12 | エシコン・インコーポレイテッドEthicon, Inc. | Hemostasis pad assembly kit and method |
US9427360B2 (en) | 2010-11-04 | 2016-08-30 | W. Jerry Mezger | Hemostatic fabric |
US9561300B2 (en) | 2011-09-26 | 2017-02-07 | Yes, Inc. | Hemostatic compositions and dressings for bleeding |
EP1587502B1 (en) | 2002-12-31 | 2017-05-31 | BSN medical GmbH | Wound dressing |
US9707311B2 (en) | 2007-08-03 | 2017-07-18 | BSN medical, GmbH | Wound care article having an absorbent shell |
JP2017221481A (en) * | 2016-06-16 | 2017-12-21 | 株式会社Quarrymen&Co. | Wound coating agent and sheet for wound coating |
US20220096708A1 (en) * | 2016-08-15 | 2022-03-31 | Guangzhou Bioseal Biotech Co. Ltd. | Hemostatic compositions and methods of making thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4453939A (en) * | 1981-02-16 | 1984-06-12 | Hormon-Chemie Munchen Gmbh | Composition for sealing and healing wounds |
US4600574A (en) * | 1984-03-21 | 1986-07-15 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Method of producing a tissue adhesive |
US4683142A (en) * | 1982-04-19 | 1987-07-28 | Eberhard Zimmermann | Resorptive sheet material for closing and healing wounds and method of making the same |
-
1997
- 1997-02-06 WO PCT/US1997/001901 patent/WO1997028832A1/en active Application Filing
- 1997-02-06 CA CA 2245585 patent/CA2245585A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4453939A (en) * | 1981-02-16 | 1984-06-12 | Hormon-Chemie Munchen Gmbh | Composition for sealing and healing wounds |
US4683142A (en) * | 1982-04-19 | 1987-07-28 | Eberhard Zimmermann | Resorptive sheet material for closing and healing wounds and method of making the same |
US4600574A (en) * | 1984-03-21 | 1986-07-15 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Method of producing a tissue adhesive |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999056798A1 (en) * | 1998-05-07 | 1999-11-11 | Genzyme Corporation | Compositions comprising hemostatic compounds and bioabsorbable polymers |
WO1999059647A1 (en) * | 1998-05-19 | 1999-11-25 | The American National Red Cross | Hemostatic sandwich bandage |
US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
US6447774B1 (en) | 1998-11-18 | 2002-09-10 | Aventis Behring Gmbh | Stabilized protein preparations for a tissue adhesive |
WO2000038752A1 (en) * | 1998-12-23 | 2000-07-06 | Aventis Behring Gmbh | Fibrin-based glue granulate and corresponding production method |
US7572769B2 (en) | 1998-12-23 | 2009-08-11 | Csl Behring Gmbh | Fibrin adhesive granulate and method for its preparation |
EP1172115A1 (en) * | 2000-02-22 | 2002-01-16 | Hogy Medical Co., Ltd. | Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
EP1172115A4 (en) * | 2000-02-22 | 2003-01-29 | Hogy Medical Co Ltd | Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
US7098315B2 (en) | 2001-01-25 | 2006-08-29 | Nycomed Pharma As | Method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
WO2002058750A2 (en) * | 2001-01-25 | 2002-08-01 | Nycomed Pharma As | A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
WO2002058750A3 (en) * | 2001-01-25 | 2002-10-31 | Nycomed Pharma As | A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
US7052713B2 (en) | 2001-02-13 | 2006-05-30 | Nycomed Pharma As | Carrier with solid fibrinogen and solid thrombin |
US7399483B2 (en) | 2001-02-13 | 2008-07-15 | Nycomed Pharma As | Carrier with solid fibrinogen and solid thrombin |
US6897348B2 (en) | 2001-12-19 | 2005-05-24 | Kimberly Clark Worldwide, Inc | Bandage, methods of producing and using same |
US6967261B1 (en) | 2001-12-28 | 2005-11-22 | Kimberly-Clark Worldwide | Bandage, methods of producing and using same |
EP1587502B1 (en) | 2002-12-31 | 2017-05-31 | BSN medical GmbH | Wound dressing |
EP1588722A4 (en) * | 2003-01-20 | 2011-03-02 | Chemo Sero Therapeut Res Inst | Hemostatic materials |
EP1588722A1 (en) * | 2003-01-20 | 2005-10-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Hemostatic materials |
EP1759718A1 (en) * | 2004-05-21 | 2007-03-07 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Tissue closing preparation |
EP1759718A4 (en) * | 2004-05-21 | 2011-03-02 | Chemo Sero Therapeut Res Inst | Tissue closing preparation |
US8609130B2 (en) | 2006-01-11 | 2013-12-17 | The University Of North Carolina At Chapel Hill | Method for activating hemostatic systems by applying a hemostatic textile |
US10058456B2 (en) * | 2006-01-11 | 2018-08-28 | Entegrion, Inc. | Hemostatic textile |
US11304852B2 (en) | 2006-01-11 | 2022-04-19 | The University Of North Carolina At Chapel Hill | Hemostatic textile |
US8377467B2 (en) | 2006-01-11 | 2013-02-19 | The University Of North Carolina At Chapel Hill | Hemostatic textile |
US8277837B2 (en) | 2006-01-11 | 2012-10-02 | Entegrion, Inc. | Hemostatic textile |
AU2007281996B2 (en) * | 2006-08-04 | 2013-06-27 | Stb, Ltd | Solid dressing for treating wounded tissue |
US20160317355A1 (en) * | 2006-08-04 | 2016-11-03 | Stb, Ltd. | Solid dressing for treating wounded tissue |
EP2059205A4 (en) * | 2006-08-04 | 2010-10-06 | Stb Lifesaving Technologies In | Processes for the production of solid dressing for treating wounded tissue |
EP2063832A4 (en) * | 2006-08-04 | 2010-10-06 | Stb Lifesaving Technologies In | Solid dressing for treating wounded tissue |
EP2063831A4 (en) * | 2006-08-04 | 2010-10-06 | Stb Lifesaving Technologies In | Solid dressing for treating wounded tissue |
EP2056756A4 (en) * | 2006-08-04 | 2010-10-06 | Stb Lifesaving Technologies In | Solid dressing for treating wounded tissue |
EP2056756A2 (en) * | 2006-08-04 | 2009-05-13 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
EP2063831A2 (en) * | 2006-08-04 | 2009-06-03 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
EP2063832A2 (en) * | 2006-08-04 | 2009-06-03 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
EP2059205A2 (en) * | 2006-08-04 | 2009-05-20 | Stb Lifesaving Technologies, Inc. | Processes for the production of solid dressing for treating wounded tissue |
US9707311B2 (en) | 2007-08-03 | 2017-07-18 | BSN medical, GmbH | Wound care article having an absorbent shell |
EP2497503A1 (en) | 2007-08-03 | 2012-09-12 | Birgit Riesinger | Haemostatic wound care article |
DE102008034364A1 (en) | 2007-08-03 | 2009-02-05 | Birgit Riesinger | Hemostatic wound care article |
US9131929B2 (en) | 2007-08-06 | 2015-09-15 | Stb, Ltd. | Methods and dressings for sealing internal injuries |
EP2752203A1 (en) * | 2008-04-25 | 2014-07-09 | Medtrade Products Ltd. | Haemostatic material |
EP2752204A1 (en) * | 2008-04-25 | 2014-07-09 | Medtrade Products Ltd. | Haemostatic material |
AU2015202402B2 (en) * | 2008-04-25 | 2016-06-16 | Medtrade Products Limited | Haemostatic material |
AU2015202401B2 (en) * | 2008-04-25 | 2016-06-16 | Medtrade Products Limited | Haemostatic material |
US20140046255A1 (en) * | 2009-09-18 | 2014-02-13 | Bioinspire Technologies, Inc. | Free-standing biodegradable patch |
US9713658B2 (en) | 2009-09-18 | 2017-07-25 | Bioinspire Technologies, Inc. | Free-standing biodegradable patch |
EP2477617B1 (en) | 2009-09-18 | 2018-01-31 | Bioinspire Technologies Inc. | Free-standing biodegradable patch |
US9192698B2 (en) | 2009-09-18 | 2015-11-24 | Bioinspire Technologies, Inc. | Free-standing biodegradable patch |
US9446103B2 (en) | 2009-09-18 | 2016-09-20 | Bioinspire Technologies, Inc. | Free-standing biodegradable patch |
US9072681B2 (en) * | 2009-09-18 | 2015-07-07 | Bioinspire Technologies, Inc. | Free-standing biodegradable patch |
US10391204B2 (en) | 2009-09-18 | 2019-08-27 | Bioinspire Technologies, Inc. | Free-standing biodegradable patch |
US9427360B2 (en) | 2010-11-04 | 2016-08-30 | W. Jerry Mezger | Hemostatic fabric |
US9561300B2 (en) | 2011-09-26 | 2017-02-07 | Yes, Inc. | Hemostatic compositions and dressings for bleeding |
US10159762B2 (en) | 2011-09-26 | 2018-12-25 | Yes, Inc. | Hemostatic compositions and dressings for bleeding |
US9056092B2 (en) | 2011-12-02 | 2015-06-16 | Ethicon, Inc. | Hemostatic bioabsorbable device with polyethylene glycol binder |
US9351883B2 (en) | 2011-12-02 | 2016-05-31 | Ethicon, Inc. | Hemostatic bioabsorbable device with polyethylene glycol binder |
WO2013082073A1 (en) | 2011-12-02 | 2013-06-06 | Ethicon, Inc. | Hemostatic bioabsorbable device with polyethylene glycol binder |
US9682174B2 (en) | 2013-03-11 | 2017-06-20 | Bioinspire Technologies, Inc. | Multi-layer biodegradable device having adjustable drug release profile |
US10159768B2 (en) | 2013-03-11 | 2018-12-25 | Bioinspire Technologies, Inc. | Multi-layer biodegradable device having adjustable drug release profile |
US9271925B2 (en) | 2013-03-11 | 2016-03-01 | Bioinspire Technologies, Inc. | Multi-layer biodegradable device having adjustable drug release profile |
JP2016523679A (en) * | 2013-07-09 | 2016-08-12 | エシコン・インコーポレイテッドEthicon, Inc. | Hemostasis pad assembly kit and method |
EP3019205B1 (en) * | 2013-07-09 | 2017-10-04 | Ethicon, Inc | Hemostatic pad assembly kit and method |
US10765774B2 (en) | 2013-07-09 | 2020-09-08 | Ethicon, Inc. | Hemostatic pad assembly kit and method |
US11400180B2 (en) | 2013-07-09 | 2022-08-02 | Ethicon, Inc. | Hemostatic pad assembly kit and method |
US20160106883A1 (en) * | 2014-10-15 | 2016-04-21 | Stb, Ltd. | Processes For Mixing Fibrinogen and Thrombin Under Conditions That Minimize Fibrin Formation While Preserving Fibrin-forming Ability, Compositions Produced by These Processes, and the Use Thereof |
JP2017221481A (en) * | 2016-06-16 | 2017-12-21 | 株式会社Quarrymen&Co. | Wound coating agent and sheet for wound coating |
US20220096708A1 (en) * | 2016-08-15 | 2022-03-31 | Guangzhou Bioseal Biotech Co. Ltd. | Hemostatic compositions and methods of making thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2245585A1 (en) | 1997-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997028832A1 (en) | Composition for sealing wounds | |
US11400180B2 (en) | Hemostatic pad assembly kit and method | |
US10076590B2 (en) | Modified starch material of biocompatible hemostasis | |
CN101455857B (en) | Biocompatibility modified starch sponges | |
EP2203053B1 (en) | Modified starch material of biocompatible hemostasis | |
US5643596A (en) | Hemostatic patch | |
US6056970A (en) | Compositions comprising hemostatic compounds and bioabsorbable polymers | |
ES2532428T3 (en) | Hemostatic sponge | |
HU227987B1 (en) | Carrier with solid fibrinogen and solid thrombin | |
CN102753203A (en) | Hemostatic sponge | |
US20220176009A1 (en) | Method for preparing absorbable haemostatic composition for body and haemostatic composition prepared thereby | |
US11484623B2 (en) | Dry pad comprising thrombin and pectin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2245585 Country of ref document: CA Ref country code: CA Ref document number: 2245585 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97528658 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |